Tridecaptin A1 (TriA1) is a non-ribosomal lipopeptide with selective antimicrobial activity against Gram-negative bacteria. Herein we show that TriA1 exerts its bactericidal effect by binding to the bacterial cell wall precursor lipid II on the inner-membrane, disrupting the proton motive force. Biochemical and biophysical assays show that binding to the Gram-negative variant of lipid II is required for membrane disruption, and that only the proton gradient is dispersed. The NMR solution structure of TriA1 in dodecylphosphocholine micelles with lipid II has been determined and molecular modeling was used to provide a structural model of the TriA1-lipid II complex. These results suggest that TriA1 kills Gram-negative bacteria by a novel mechanism of action using a new lipid II binding motif.
Introduction
Recently, a lot of media coverage has been focused on the problem of antimicrobial resistance. A report commissioned by the UK government predicts that by 2050, antimicrobial resistance will have caused 300 million premature deaths and cost the global economy over $100 trillion.(1) Even more worrying is the lack of new classes of antibiotics active against Gram-negative bacteria. In the last 50 years, only a few structurally and mechanistically distinct classes of antibiotics have been clinically approved to treat systemic infections (including fidaxomicin, bedaquiline, linezolid and daptomycin), yet none of these are active against Gram-negative bacteria. (2) , (3) Two new classes of Gram-negative targeting antibiotics in the clinical pipeline are POL7080 and brilacidin.(4), (5) Both of these compounds are modeled on antimicrobial peptides, which are becoming increasing important in the fight against antibiotic resistance.(6) Bacteria produce a wealth of antimicrobial peptides, both ribosomally, including the lantibiotics, (7) , (8) and non-ribosomally, including lipopeptides. (9) In particular, lipopeptides are a rich source of antimicrobial compounds and several examples with activity against Gram-positive(10), (11) and/or Gram-negative bacteria (12) have been recently characterized.
Tridecaptin A1 (TriA1) is a member of the tridecaptin family, a group of non-ribosomal lipopeptides produced by Bacillus and Paenibacillus species ( Fig.   1 ). (13) , (14) , (15) This acylated tridecapeptide displays strong and selective antimicrobial activity against Gram-negative bacteria, including multidrug resistant strains of Klebsiella pneumoniae, Acinetobacter baumannii and Escherichia coli. (16) TriA1 analogues have low cytotoxicity and have been shown to treat Klebsiella pneumoniae infections in mice. (16) , (17) Therefore, we believe that tridecaptin A1 could be an excellent antibiotic candidate. However, prior to our investigations little was known about how TriA1 exerts its selective bactericidal effect against Gram-negative bacteria. A previous structure activity relationship study by our group suggested that TriA1, akin to many other lipopeptides, is a membrane-targeting agent. We found that removal of the Nterminal lipid tail abolishes antimicrobial activity, however the chiral lipid tail could be replaced with an octanoyl chain to give Oct-TriA1 ( Fig. 1) , which retains full activity. (16) We therefore sought to identify the precise mode and mechanism of action by which TriA1 kills Gram-negative bacteria.
Results

Tridecaptin A1 targets the cell membrane
Our initial efforts focused on identifying the mode of action of TriA1.
Measuring the time taken for an antibiotic to exert its antimicrobial effect can provide valuable information on the cellular process targeted by that compound.
Bacteriostatic agents halt cell division but do not reduce the number of viable cells and antibiotics that target protein synthesis and nucleic acid synthesis typically fall within this category. Bactericidal agents reduce the population of viable bacterial cells and the time taken for a bactericidal agent to kill bacteria provides further information on its target. Therefore, we monitored the growth kinetics of Escherichia coli cells exposed to TriA1 and a number of other antibiotics ( Fig. 2 ). Lipopeptides like polymyxin B are generally bactericidal within minutes of exposure, due to the formation of large, non-specific pores in the bacterial membrane, while many other antibiotics (like ampicillin) exert their killing effect over several hours. Bacteriostatic agents (like chloramphenicol) halt cell growth, but do not kill cells. Optical density measurements showed that cells exposed to TriA1 grew at a reduced rate for 20 minutes, at which point a steady decrease in cell count was observed ( Fig. 2A ). Polymyxin B reduced the cell count immediately, while ampicillin displayed an expected three-hour lag and chloramphenicol did not reduce optical density. Complementary results were obtained from a time-kill assay ( Fig. 2B ), which revealed that cells exposed to TriA1 showed slightly reduced cell viability after 15 minutes of exposure, a significant reduction after 30 minutes and complete killing after 60 minutes.
Polymyxin B acted faster, significantly reducing the viable cell population after 5 minutes and killing all cells by 30 minutes. These results suggested that TriA1 is a membrane targeting peptide, but does not act by a generic membrane lysis mechanism like polymyxin B. This is further supported by the selectivity of TriA1 against Gram-negative bacteria, as a peptide that operates through a generic lysis mechanism would also target Gram-positive organisms.
TriA1 binds to lipopolysaccharide on the outer-membrane
Gram-negative organisms are protected from their environment by an outer-membrane, which reduces diffusion of many antibiotics into the cell or periplasmic space. In order for TriA1 to attack the bacterial membrane of Gramnegative bacteria, it must first cross this barrier. Polymyxin B traverses the outermembrane by binding to the lipid A portion of lipopolysaccharide (LPS), followed by insertion into the membrane. (18) We postulated that tridecaptin A1 may also cross the outer-membrane through an interaction with LPS, given that it possess several cationic 2,4-diaminobutyric acid residues (Dab) like polymyxin B.
Isothermal titration calorimetry (ITC) was therefore used to determine if TriA1 binds to LPS. Our studies revealed that TriA1, Oct-TriA1, the enantiomeric form of TriA1 (Ent-TriA1) and unacylated TriA1 (H-TriA1) bind to LPS with similar affinities (SI Appendix, Fig. S1 ). We have previously shown that H-TriA1 has weak antimicrobial activity, but at sub-MIC concentrations it can enhance the activity of hydrophobic antibiotics like rifampicin and vancomycin over 100-fold. (17) Therefore, it is likely that LPS binding is the mechanistic basis for this disruption of the outer-membrane. We have also found that the enantiomer of TriA1 (Ent-TriA1) is four-fold less active than the natural peptide, suggesting that TriA1 interacts with a chiral target. (19) Ent-TriA1 contains the same amino acids and lipid tail as TriA1, and therefore retains the same amphiphilic properties. It is likely that the observed activity at higher concentrations is due to membrane lysis by a non-specific detergent-like effect, akin to the mode of action of the polymyxins.
This observation that both TriA1 and its enantiomer bind to LPS with similar affinities suggested that another chiral receptor is involved in the mode of action.
TriA1 disrupts the proton motive force
With a rationale for how TriA1 crosses the outer-membrane, we next sought to uncover the mechanism by which it acts on the inner-membrane. To this end, a series of experiments were performed using fluorescent dyes ( Fig. 3 ).
DiBAC4 is a common dye used to monitor membrane depolarization. (20) It enters depolarized cells and binds to proteins or membrane components, exhibiting enhanced fluorescence. Addition of TriA1 to DiBAC4 treated E. coli cells resulted in no membrane depolarization, whilst application of polymyxin B lead to a rapid increase in fluorescence ( Fig. 3A ). To further assess the effect of TriA1 on the inner-membrane, its ability to form large pores was assessed using the dye SYTOX Green (Fig. 3B ). Upon lysis of the inner-membrane, this dye binds to nucleic acids in the cytoplasm, causing an increase in fluorescence. (21) Immediate pore formation was not observed when E. coli cells pretreated with SYTOX Green were exposed to TriA1, whereas addition of the surfactant Triton X-100 caused an instant fluorescence increase. Instead, TriA1 caused a very gradual increase in fluorescence at a rate consistent with the death of cells based on the time-kill assays, suggesting that this increase is due to cells that are already dead and not an immediate effect of TriA1. To further probe the action of TriA1 on the inner membrane, an ortho-nitrophenyl-β-galactosidase The rapid killing of E. coli by TriA1 stood in stark contrast to the lack of membrane lysis or depolarization observed. The essential nature of the hydrophobic tail for antimicrobial activity and the overall amphiphilic structure of TriA1 support an interaction with the bacterial membrane, therefore we examined the function of the inner-membrane in detail. Bacteria use both protons and potassium ions to generate adenosine triphosphate (ATP) via the proton motive force, a process that is essential for cell growth. (22) ,(23) Other antibiotics are known to affect this vital cellular process. For example, nigericin and valinomycin shuttle a combination of K + and H + across the bacterial membrane,(23) while the bacteriocin subtilosin forms proton-specific pores in the Gram-positive bacterium Gardnerella vaginalis. (24) , (25) To determine if TriA1 affects the proton motive force, we adapted the pro-dye BCECF-AM for use in Gram-negative bacteria. In the presence of ethylenediaminetetraacetic acid (EDTA), this dye readily crosses the bacterial membrane where it is hydrolyzed by non-specific esterases to give a pH sensitive dye, whose fluorescence decreases as cytoplasmic pH decreases. (25) Addition of glucose to BCECF-AM treated E. coli cells resulted in a fluorescence increase, indicating they were actively respiring and that BCECF was correctly showing the increase in cytoplasmic pH ( Fig. 3C ). To assess the effect on the proton gradient, the potassium gradient was first dispersed by addition of valinomycin, which exchanges K + with H + , causing a small increase in fluorescence. Subsequent addition of TriA1 resulted in a significant fluorescence decrease, signifying pore formation and disruption of the proton gradient.
Addition of the proton shuttle peptide nigericin also had a similar but more rapid effect, strongly suggesting that TriA1 disrupts the proton motive force.
TriA1 selectively binds to Gram-negative lipid II
Having identified a probable mode of action for tridecaptin A1, we next sought to identify the chiral receptor involved in its mechanism of action. Given the lower antimicrobial activity of the Ent-TriA1, and the fact that TriA1 acts on the bacterial membrane, we postulated that binding of TriA1 to a chiral receptor on S4 ). To the best of our knowledge, this is the first reported instance of an antimicrobial compound binding selectively to lipid II from Gram-negative bacteria.
In vitro assays link lipid II binding to membrane disruption
To corroborate our theory that TriA1 binds to lipid II on the innermembrane and disrupts the proton motive force, we developed an in vitro assay using large unilamellar vesicles (LUV) and BCECF acid to measure intravesicle pH changes. BCECF was encapsulated in 50 nm LUVs, such that the internal pH is set to pH 8.0 ( Fig. 5A ). Transferring these vesicles into a pH 6 buffer did not lead to an observable change in fluorescence over 30 minutes of incubation, whilst an immediate decrease was observed on the addition of triton X-100, confirming the integrity of the vesicles. Oct-TriA1, which has identical antimicrobial activity to TriA1 and also binds to Gram-negative lipid II, was used in these studies. Addition of Oct-TriA1 to LUVs containing 1 mol% Gram-negative lipid II at concentrations mimicking the bacterial MIC resulted in a rapid decrease in fluorescence, signifying pore formation ( Fig. 5B) . A much weaker decrease in fluorescence occurred with LUVs containing 1 mol% Gram-positive lipid II, which was comparable to the effect observed against vesicles lacking any lipid II.
These studies provide further evidence that TriA1 selectively recognizes Gramnegative lipid II and link this recognition to the observed bactericidal activity.
Synthesis of Gram-negative lipid II analogue for NMR studies
In an effort to understand the interaction between TriA1 and Gramnegative lipid II on a molecular level, we sought to elucidate the NMR solution structure of TriA1 in dodecylphosphocholine (DPC) micelles containing Gramnegative lipid II. Natural lipid II, which contains a fatty undecaprenyl chain, is not very amenable to NMR studies. It is prone to micelle formation in aqueous solvent and the multiple methyl and methylene signals from the C55 chain can drown out important signals in its binding partner needed for complete structural characterization. Breukink and coworkers have previously shown that a Grampositive lipid II analogue with an (E,E)-farnesyl (C15) chain retains full binding affinity to nisin, (29) and this analogue was used in the elucidation of the NMR solution structure of the nisin-lipid II complex. (27) Although they found that the isoprene units in the chain were not necessary for nisin binding, it was unclear if this region of lipid II was required for interactions with TriA1. Therefore we embarked on the synthesis of (Z,Z)-farnesyl Gram-negative lipid II (1) (Fig. 6 ).
The total synthesis of Gram-positive lipid II was previously reported by Van Nieuwenhze and coworkers,(30),(31) whereas a semi-synthesis of Gram-negative lipid II has been reported by Walker and Kahne.(32) By modification of these literature procedures, we performed the first total synthesis of Gram-negative lipid II analogue (1) (Fig. 6 , SI Appendix). The disaccharide core was constructed by a glycosylation between acetimidate 2 (SI Appendix, Scheme S1) and glycol 3 (SI Appendix, Scheme S2-S3). After protecting group manipulation and phosphorylation of the anomeric position of alanyl disaccharide 4, the appropriate tetrapeptide (5, SI Appendix, Scheme S4-S5) was coupled to the alanine carboxylate to yield pentapeptidyl disaccharide 6. Deprotection of the benzyl phosphate, followed by coupling to CDI activated (Z,Z)-farnesyl phosphate and global deprotection gave the desired Gram-negative lipid II analogue 1.
Characterization of TriA1-lipid II complex by NMR and molecular modeling
With Gram-negative lipid II analogue 1 in hand, we then proceeded to elucidate the NMR solution structure of Oct-TriA1 in DPC micelles doped with Gram-negative lipid II. First, the chemical shifts (SI Appendix, Table S1 ) and
Nuclear Overhauser Effect (NOE) correlations of Oct-TriA1 in DPC micelles were assigned and its solution structure calculated using CYANA (SI Appendix, Fig.   S5 ).(33) Without lipid II, Oct-TriA1 adopts a looped structure with all hydrophobic residues on one face. Upon addition of one equivalent of lipid II analogue 1 (SI Appendix, Table S2) more open and amphiphilic structure with an apparent π-stacking interaction between D-Trp5 and Phe9 (Fig. 7A) . Interestingly, D-Dab8, which we have previously shown is the critical residue for Oct-TriA1 activity, (19) is located at the base of a possible binding pocket.
To obtain an experimentally derived model of the Oct-TriA1-Lipid II complex, the structure of lipid II analogue 1 in the presence of Oct-TriA1 was also calculated using CYANA and then docked into the NMR solution structure of Oct-TriA1 (Fig. 6A) using AutoDock Vina (Fig. 7B) . (34) The model suggests that the N-terminal lipid tail and D-Trp5 are in close proximity to the lipid II terpene chain.
This would be expected as the terpene tail of lipid II anchors it to the exterior of the inner-membrane and would associate with the more hydrophobic residues of TriA1. The model also suggests there is a H-bonding interaction between the γamino group of D-Dab8 and the ε-carboxylate on DAP3 in lipid II (Fig. 7C ). D-Dab8 is essential for the antimicrobial activity of the tridecaptins and DAP3 in lipid II is essential for TriA1 binding. Notably, the model does not show interactions between Oct-TriA1 and the pyrophosphate moiety of lipid II. No shift in the 31 P-NMR of lipid II is observed on addition of Oct-TriA1, confirming that the pyrophosphate is not involved in Oct-TriA1 binding (SI Appendix, Fig. S8 ). To the best of our knowledge, this is the first reported instance of an antimicrobial peptide that does not make use of a pyrophosphate cage.
TriA1 displays low levels of resistance development
The results from the mode of action and mechanism of actions studies suggested that tridecaptin A1 exerts its bactericidal effect by binding to lipid II on the inner-membrane and disrupting the proton motive force. Lipid II is a late stage intermediate in peptidoglycan biosynthesis, and the proposed binding site for TriA1 would be difficult for bacteria to modify without affecting its subsequent processing by enzymes in the peptidoglycan biosynthesis pathway. One would therefore expect that resistance development against TriA1 would be limited. An in vitro evolution study was performed, in which E. coli cells were continuously exposed to sub-MIC concentrations of Oct-TriA1 or ciprofloxacin for one month.
During this experiment, the activity of the nucleic acid synthesis inhibitor ciprofloxacin decreased eight-fold, whereas no persistent resistance developed against Oct-TriA1 (Fig. 8 ).
Discussion
We have shown that tridecaptin A1 exerts its bactericidal effect on Gramnegative bacteria by binding to lipid II on the surface of the inner-membrane and disrupting the proton motive force. Monitoring the time taken for TriA1 to kill E. coli cells by growth kinetic measurements and time-kill assays suggested that it targets the cell membrane (Fig. 2 ). However, it does not act as quickly as polymyxin B, which kills bacteria by forming large non-specific pores on the inner-membrane. A study of the effect that TriA1 has on the bacterial membrane using fluorescent dyes ( Fig. 3 ) revealed that TriA1 does not depolarize the membrane or kill Gram-negative bacteria by the formation of large pores. Initially this result was quite surprising as several pieces of evidence suggested that it interacts with the cell membrane. Firstly, the lipid tail of TriA1 is essential to its antimicrobial activity. This is similar for many other lipopeptides, which must insert their lipid tail into the cell membrane for membrane disruption. Also, the time taken by TriA1 to kill Gram-negative bacteria is consistent with membrane acting antibiotics and its overall amphiphilic structure further suggested a membrane interaction. This lead us to consider that TriA1 targets the bacterial membrane by a mode of action that is not membrane lysis. The proton motive force is a vital process that occurs across the bacterial membrane because it is the primary method by which bacteria produce ATP. The observation that other peptide antibiotics like nigericin, valinomycin and subtilosin can disrupt the proton motive force lead us to develop an in vivo assay using BCECF-AM to assess the impact that TriA1 has on this important cellular function. This experiment showed that addition of TriA1 rapidly decreases the cytoplasmic pH of E. coli cells, which was visualized as a rapid decrease in fluorescence (Fig. 3C ). This signifies the formation of pores, allowing the transport of protons from the more acidic extracellular buffer into the cytoplasm. Combining this result with the observation that TriA1 does not depolarize the bacterial membrane or form large pores led us to conclude that TriA1 forms proton specific pores. This will ultimately block the synthesis of ATP and kill bacteria.
Having identified a probable mode of action, we next became interested in the mechanism of action. ITC revealed that like polymyxin B, TriA1 binds to LPS on the outer-membrane of Gram-negative bacteria. Removal of the lipid tail from TriA1 does not affect LPS binding but the unacylated derivative of TriA1 has substantially lower activity than the natural peptide. Therefore, the lipid tail is important for either outer-or inner-membrane penetration. The observation that the enantiomer of TriA1, which is less active than TriA1, binds to LPS with a similar binding affinity shows that another chiral receptor is involved in the mechanism of action. As several other antimicrobial peptides bind to the peptidoglycan precursor lipid II, which is presented on the surface of the innermembrane, we investigated if this was also a target for TriA1. A combination of ITC (Fig. 4B, SI Appendix, Fig. S1 ), inhibition assays ( Fig. 4C ) and in vitro assays (Fig. 5 ) provided compelling evidence that TriA1 selectively binds to the Gram-negative variant of lipid II, which contains DAP rather than lysine on its pentapeptide chain. TriA1 has strong activity against Gram-negative bacteria and strongly binds to lipid II from these organisms. Its activity is sequestered through complex formation with this analogue and the presence of Gram-negative lipid II in model membranes substantially increases the pore forming ability of TriA1.
With TriA1 having much lower activity against Gram-positive bacteria, one would expect it to not bind very strongly to lipid II from these organisms, not lose activity when mixed with Gram-positive lipid II and not show increased activity against model membranes doped with Gram-positive lipid II. This is exactly what our experiments show.
We synthesized an analogue of Gram-negative lipid II and used this to calculate the NMR solution structure of tridecaptin A1 in DPC micelles containing one equivalent of Gram-negative lipid II (Fig. 7A ). Molecular docking studies were then used to produce a model of the TriA1-lipid II complex ( Fig. 7B-7C ), which is supported by several lines of experimental evidence. Firstly, the amide chemical shifts of lipid II that underwent the largest change upon addition of Oct-TriA1 are on the pentapeptide portion. Secondly, no interaction is predicted with the pyrophosphate of lipid II and no change in the 31 P-NMR upon addition of Oct-TriA1 to lipid II analogue 1 was observed. Thirdly and most importantly, a key hydrogen bond is predicted between the γ-amino group of D-Dab8 and the εcarboxylate on DAP3 in lipid II. A previous SAR study showed that D-Dab8 is absolutely essential for activity, and its substitution to D-Ala decreases its activity against Gram-negative bacteria to the level observed against Gram-positive organisms. If residue three on the pentapeptide portion of lipid II is lysine rather than DAP, the binding affinity of TriA1 is significantly reduced. Therefore, this predicted interaction perfectly describes these experimental observations and led us to conclude that it is the presence of DAP on lipid II that gives rise to the remarkable selectivity of tridecaptin A1 against Gram-negative bacteria. The observation that resistance development against Oct-TriA1 is limited (Fig. 8) is also important, given the lack of new antibiotics that target Gram-negative bacteria, and we believe that the tridecaptins are an attractive class of future antibiotic candidates.
Materials and Methods
Whole cell studies: See supplementary information. Water suppression was achieved by presaturation during the relaxation delay.
For NOESY, saturation of the water peak was also applied during the mix time.
NMRPipe and NMRView were used for data processing. Chemical shift assignments were performed manually. After complete spectral assignment of 
Figure legends
